NDA 211911 · Abbvie
Durysta
Bimatoprost · Ophthalmic · Prostaglandin Analog
Last checked: Nov 20, 2026Latest source record: Oct 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Mar 4, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
147
39 Phase 3, 7 recruiting
FAERS reports
2,818
1,650 serious, 129 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2024.
DURYSTA ® (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). DURYSTA is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). ( 1 )
Mechanism: Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- DURYSTA · BIMATOPROST 10MCG · IMPLANT, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bimatoprost" as an intervention, any sponsor and status, largest first.
AllerganAbbVie (ABBV)
NCT01833741 · 1,137 participants · Start Dec 2009 · Primary completion Mar 2011
Drug: Bimatoprost 0.01% · For: Glaucoma, Primary Open Angle; Ocular Hypertension
Sites: Barrie, Canada
- Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01298700 · 806 participants · Start May 31, 2011 · Primary completion Dec 6, 2016
Drug: bimatoprost 0.01% ophthalmic solution; bimatoprost 0.03% ophthalmic solution · For: Glaucoma; Ocular Hypertension
Sites: Leuven, Belgium; Liège, Belgium; Brno, Czechia · 50 sites in all
AllerganAbbVie (ABBV)
NCT01594970 · 800 participants · Start Mar 2012 · Primary completion Jan 2013
Drug: Bimatoprost 0.01% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Seoul, South Korea
AllerganAbbVie (ABBV)
NCT02571712 · 750 participants · Start Nov 10, 2015 · Primary completion Jun 21, 2018
Drug: bimatoprost 0.03% plus timolol 0.5% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsPivotal-lookingCompleted
Laboratoires TheaIndustry
NCT05397600 · 684 participants · Start Jun 22, 2022 · Primary completion Mar 7, 2024
Drug: Bimatoprost Ophthalmic · For: Glaucoma; Ocular Hypertension
Sites: Chandler, Arizona; Glendale, Arizona; Phoenix, Arizona · 64 sites in all
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
YS Life Science Co., Ltd.Industry
NCT07661329 · 600 participants (planned) · Start Jun 2, 2026 · Primary completion Nov 1, 2027
Drug: Bimatoprost ophthalmic solution 0.01% YSBP; bimatoprost ophthalmic solution 0.01% (Lumigan®) · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OH)
Sites: Beverly Hills, California; Inglewood, California; Newport Beach, California · 22 sites in all
- Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01099774 · 597 participants · Start May 1, 2010 · Primary completion Apr 29, 2011
Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution; Bimatoprost 0.03% Ophthalmic Solution · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02247804 · 594 participants · Start Dec 15, 2014 · Primary completion Feb 19, 2018
Drug: Bimatoprost SR; Active Comparator: Timolol 0.5% and 1 more · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Phoenix, Arizona; Glendale, California; Irvine, California · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective268
- intraocular pressure increased113
- ocular hyperaemia108
- no adverse event107
- eye irritation93
- eye pain92
- nausea80
- dyspnoea78
- vision blurred73
- diarrhoea71
- fatigue71
- headache71
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 21 |
| 2009 | 22 |
| 2010 | 23 |
| 2011 | 36 |
| 2012 | 21 |
| 2013 | 51 |
| 2014 | 65 |
| 2015 | 82 |
| 2016 | 119 |
| 2017 | 207 |
| 2018 | 180 |
| 2019 | 198 |
| 2020 | 237 |
| 2021 | 299 |
| 2022 | 232 |
| 2023 | 299 |
| 2024 | 238 |
| 2025 | 238 |
| 2026 | 216 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Durysta (Bimatoprost)
2024 spending
$1.3M
Beneficiaries
360
383 claims
Per beneficiary
$3,706
$1,979.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,016 |
| 2021 | $217,275 |
| 2022 | $697,834 |
| 2023 | $965,229 |
| 2024 | $1,334,075 |
Part B: Durysta (Bimatoprost) · HCPCS J7351
2024 spending
$20.7M
Beneficiaries
6,292
10,009 claims
Per beneficiary
$3,290
2024 ASP limit $207.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,870,998 |
| 2021 | $21,888,390 |
| 2022 | $21,215,843 |
| 2023 | $21,795,947 |
| 2024 | $20,702,805 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, et al. · Graefes Arch Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Multicenter Study
- Treatments for alopecia areata: A systematic review and network meta-analysis.
Fukumoto T, Fukumoto R, Magno E, et al. · Dermatol Ther 2021 · Systematic Review, Network Meta-Analysis
- Bimatoprost vs. timolol.
Camras CB · Ophthalmology 2002 · Clinical Trial, Comment
- Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.
Lee SS, Burke J, Shen J, et al. · Vet Ophthalmol 2018 · Randomized Controlled Trial
- Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study.
Zaher H, Gawdat HI, Hegazy RA, et al. · Dermatology 2015 · Comparative Study, Randomized Controlled Trial
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.